Update on Prognostic and Predictive Biomarkers for Pancreatic Neuroendocrine Tumors

  • Paul Eliezer Oberstein Columbia University College of Physicians and Surgeons at New York Presbyterian Hospital. New York, NY, USA
  • Muhammad Wasif Saif Tufts University School of Medicine. Boston, MA, USA
Keywords: Biological Markers, Neoplastic Cells, Circulating, Neuroendocrine Tumors, Pancreatic Neoplasms, placenta growth factor


Neuroendocrine tumors (NETs) describe a heterogeneous group of tumors with a wide range of morphologic, functional, and behavioral characteristics. These tumors are often indolent but they have the potential to cause symptoms through release of hormones and through local or distant spread. Pancreatic neuroendocrine tumors (pNET) represent a subset of NETs and they have a unique pattern of symptoms and disease progression. Due to the heterogeneity of this disease it is important to identify reliable markers to help guide prognosis and predict response to therapy. The recent approval of two new agents in the treatment of advanced pNET has raised additional interest in the significance of molecular markers in this disease. At the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, several investigators reported on collaborative efforts to develop clinically useful biomarkers for this disease. Choti et al. (Abstract #4126) reported data about the functional characteristics of NETs and pNETs among a multi-institutional cohort finding that a substantial minority of patients have functional symptoms even when the disease is localized. Faggiano et al. (Abstract #1604) looked at a wide spectrum of NETs in several referral centers and reported on predictors of both short term and long term survival in this setting. Yao et al. (Abstract #4014) reported analysis of predictive biomarkers among patients in the RADIANT-2 trial which looked at the role of the mTOR inhibitor, everolimus compared to placebo in NET. Fischer et al. (Abstract #4128) looked at a novel biomarker, placental growth factor (PlGF) and evaluated the role of serum and tissue levels of this protein as a predictive marker. Finally, Khan et al. (Abstract #4123) investigated the role of circulating tumor cells in NET (and pNET) and found that this may have potential as a prognostic marker and an early marker of response to therapy. The authors review and summarize these abstracts in this article.

Image: Bard Haven Towers, Columbia University Medical Center. New York City, NY, USA (Summer time).


Download data is not yet available.


Barker N, van Es JH, Kuipers J, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007;449:1003-7.

Jensen RT. Carcinoid tumors and the carcinoid syndrome. In: De Vita VTJ, Lawrence, T., Rosenberg, S.A., ed. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott, Williams, and Wilkins; 2008.

Zornosa CC, Choti MA, Bobiak S, et al. Baseline demographics of neuroendocrine tumor patients presenting to seven National Comprehensive Cancer Network (NCCN) institutions: Development of a multi-institutional outcomes database. J Clin Oncol 30, 2012 (suppl; abstr e14551).

Yao JC, Eisner MP, Leary C, et al. Population-based study of islet cell carcinoma. Ann Surg Oncol 2007;14:3492-500.

Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72.

Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002;20:2633-42.

Vagefi PA, Razo O, Deshpande V, et al. Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005. Arch Surg 2007;142:347-54.

Jensen RT, Berna MJ, Bingham DB, Norton JA. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 2008;113:1807-43.

Zikusoka MN, Kidd M, Eick G, Latich I, Modlin IM. The molecular genetics of gastroenteropancreatic neuroendocrine tumors. Cancer 2005;104:2292-309.

Zhang J, Jia Z, Li Q, et al. Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 2007;109:1478-86.

Terris B, Scoazec JY, Rubbia L, et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 1998;32:133-8.

Choti MA, Bobiak S, Strosberg JR, et al. Prevalence of functional tumors in neuroendocrine carcinoma: An analysis from the NCCN NET database. J Clin Oncol 30, 2012 (suppl; abstr 4126)

Faggiano A, Grimaldi F, Manzoni M, et al. Long-term survival and prognostic factors in neuroendocrine tumors: Results from a large multicenter study. J Clin Oncol 30, 2012 (suppl; abstr 1604).

Yao JC, Hainsworth JD, Wolin EM, et al. Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET). J Clin Oncol 30, 2012 (suppl; abstr 4014).

Khan MS, Tsigani T, Garcia-Hernandez J, Hartley JA, Caplin ME, Meyer T. Circulating tumor cells as prognostic and predictive markers in neuroendocrine tumors. J Clin Oncol 30, 2012 (suppl; abstr 4123)

Riethdorf S, Fritsche H, Muller V, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007;13:920-8.

Fischer C, Pape U-F, Neumann T, et al. Prognostic relevance of circulating PIGF levels in patients with neuroendocrine tumors. J Clin Oncol 30, 2012 (suppl; abstr 4128)

Bard Haven Towers, Columbia University Medical Center. New York City, NY, USA (Summer time)
How to Cite
ObersteinP., & SaifM. (2012). Update on Prognostic and Predictive Biomarkers for Pancreatic Neuroendocrine Tumors. JOP. Journal of the Pancreas, 13(4), 368-371. https://doi.org/10.6092/1590-8577/965
Highlights from the “2012 ASCO Annual Meeting”. Chicago, IL, USA. June 1-5, 2012

Most read articles by the same author(s)

1 2 3 > >>